Published in Pediatr Blood Cancer on October 19, 2011
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia | NCT00006400
Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy (2012) 1.66
Update on the use of hydroxyurea therapy in sickle cell disease. Blood (2014) 0.93
From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore) (2014) 0.82
Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. J R Soc Med (2016) 0.77
Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica (2014) 0.77
Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. J Clin Pharmacol (2015) 0.76
Pediatric sickle cell disease: past successes and future challenges. Pediatr Res (2016) 0.75
Translating sickle cell guidelines into practice for primary care providers with Project ECHO. Med Educ Online (2016) 0.75
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
Leukocytes cultured from small inocula of whole blood and the preparation of metaphase chromosomes by treatment with hypotonic KCl. Stain Technol (1965) 4.37
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 3.09
How I use hydroxyurea to treat young patients with sickle cell anemia. Blood (2010) 2.68
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med (2008) 2.43
Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics (2008) 2.42
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest (2005) 2.36
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med (2008) 2.31
Mechanism of action of hydroxyurea. Semin Oncol (1992) 2.23
SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol (2002) 2.13
Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program (2009) 1.40
Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood (2000) 1.29
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res (2010) 1.24
Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood (2004) 1.22
Human thymic epithelial cells function as accessory cells for autologous mature thymocyte activation. J Immunol (1987) 1.21
Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol (2007) 1.06
Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen (2007) 1.03
Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutat Res (1985) 1.01
Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol (2011) 0.99
DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res (2007) 0.98
Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds. Cancer Res (1965) 0.97
Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damage. Mutat Res (2006) 0.92
A simple assay for frequency of chromosome breaks and loss (micronuclei) by flow cytometry of human reticulocytes. FASEB J (2004) 0.89
Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clin Exp Med (2006) 0.86
Pilot study for comparison of reticulocyte-micronulei with lymphocyte-micronuclei in human biomonitoring. Toxicol Lett (2005) 0.82
Analysis of mutagenic V(D)J recombinase mediated mutations at the HPRT locus as an in vivo model for studying rearrangements with leukemogenic potential in children. DNA Repair (Amst) (2006) 0.81
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med (2004) 3.33
Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. Am J Hum Genet (2003) 3.01
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
Translocation of single-stranded DNA through single-walled carbon nanotubes. Science (2010) 2.50
Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet (2011) 2.48
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Direct, noncatalytic mechanism of IKK inhibition by A20. Mol Cell (2011) 2.32
Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood (2010) 2.25
Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell (2009) 2.18
The diagnostic pathway to sarcoidosis. Chest (2003) 2.15
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood (2007) 2.13
Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr (2003) 2.11
Role of hPHF1 in H3K27 methylation and Hox gene silencing. Mol Cell Biol (2007) 2.10
Identifying single bases in a DNA oligomer with electron tunnelling. Nat Nanotechnol (2010) 2.08
A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol (2013) 2.06
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem (2008) 2.04
MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer (2008) 2.01
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet (2002) 1.99
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest (2011) 1.89
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood (2011) 1.88
Electronic signatures of all four DNA nucleosides in a tunneling gap. Nano Lett (2010) 1.83
Th9 cells promote antitumor immune responses in vivo. J Clin Invest (2012) 1.80
Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.75
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) (2004) 1.67
Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood (2012) 1.66
Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.60
The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol (2014) 1.58
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res (2009) 1.55
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood (2011) 1.54
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer (2005) 1.51
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.50
Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res (2005) 1.50
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol (2013) 1.49
Recognition tunneling. Nanotechnology (2010) 1.47
Bone marrow transplant options and preferences in a sickle cell anemia cohort on chronic transfusions. Pediatr Blood Cancer (2012) 1.46
Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am (2008) 1.43
Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood (2012) 1.43
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr (2010) 1.43
Conductance of single alkanedithiols: conduction mechanism and effect of molecule-electrode contacts. J Am Chem Soc (2006) 1.42
Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood (2012) 1.37
Kdm2b promotes induced pluripotent stem cell generation by facilitating gene activation early in reprogramming. Nat Cell Biol (2012) 1.35
Tunnelling readout of hydrogen-bonding-based recognition. Nat Nanotechnol (2009) 1.35
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer (2008) 1.30
Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol (2004) 1.30
Hemozoin-generated vapor nanobubbles for transdermal reagent- and needle-free detection of malaria. Proc Natl Acad Sci U S A (2013) 1.28
New and emerging technologies for genetic toxicity testing. Environ Mol Mutagen (2010) 1.28
Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood (2011) 1.26
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood (2011) 1.25
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res (2010) 1.24
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res (2008) 1.23
In vivo mutation assay based on the endogenous Pig-a locus. Environ Mol Mutagen (2008) 1.20
The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J (2011) 1.20
Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol (2011) 1.19
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol (2011) 1.18
Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg (2003) 1.18
In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutat Res (2007) 1.16
Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol (2011) 1.14
Genetic predictors for stroke in children with sickle cell anemia. Blood (2011) 1.12
Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res (2005) 1.12
Adherence to study medication and visits: data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.12
A molecular switch based on potential-induced changes of oxidation state. Nano Lett (2005) 1.11
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica (2010) 1.10
Gap distance and interactions in a molecular tunnel junction. J Am Chem Soc (2011) 1.10
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) (2011) 1.10
Chemical recognition and binding kinetics in a functionalized tunnel junction. Nanotechnology (2012) 1.09
Novel SLC20A2 mutations identified in southern Chinese patients with idiopathic basal ganglia calcification. Gene (2013) 1.07
Interactions of the yeast SF3b splicing factor. Mol Cell Biol (2005) 1.07
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr (2002) 1.07
Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease: pouch retention and implications of delayed diagnosis. Ann Surg (2008) 1.07
In vitro micronucleus scoring by flow cytometry: differential staining of micronuclei versus apoptotic and necrotic chromatin enhances assay reliability. Environ Mol Mutagen (2006) 1.06
Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatr Blood Cancer (2010) 1.06
Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol (2007) 1.06
Pig-a mutation: kinetics in rat erythrocytes following exposure to five prototypical mutagens. Toxicol Sci (2009) 1.06
Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol (2013) 1.06
Sublethal radiation injury uncovers a functional transition during erythroid maturation. Exp Hematol (2011) 1.05
HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc (2011) 1.05
Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem (2006) 1.05